MétaCan
Menu
← Back to cohort
Record W4406699190 · doi:10.1093/ecco-jcc/jjae190.0951

P0777 Sonographic transmural induction outcomes across advanced therapies in Crohn’s Disease

2025· article· en· W4406699190 on OpenAlexaff
Matthew D. Smyth, Michael T. Dolinger, M Dubinsky

Bibliographic record

VenueJournal of Crohn s and Colitis · 2025
Typearticle
Languageen
FieldBiochemistry, Genetics and Molecular Biology
TopicInflammatory Bowel Disease
Canadian institutionsUniversity of British Columbia
Fundersnot available
KeywordsMedicineCrohn's diseaseDiseaseInternal medicineIntensive care medicine

Abstract

fetched live from OpenAlex

Abstract Background Intestinal ultrasound (IUS) is increasingly being used to evaluate induction efficacy in both clinical practice and clinical trials. The differential healing rates across advanced therapies (AT) remains unknown. We aimed to quantify the rates of early post induction IUS transmural (TM) remission and response across AT in Crohn’s Disease (CD). Methods Single center retrospective review of patients with CD initiating AT who underwent IUS pre and post induction and had disease activity and biomarker data available. Patients with normal pre-AT IUS or post op were excluded. Primary outcome was post-induction TM response of the most affected segment (segmental response compared to baseline: >25% decrease in bowel wall thickness (BWT), absolute BWT decrease >2mm, or absolute decrease >1mm with ≥1-point improvement in Modified Limberg Score (MLS)). Secondary outcomes were segmental and complete (all bowel segments) TM remission (BWT ≤ 3.0mm and MLS 0). Descriptive statistics summarized data (median [IQR]), univariate and multivariate analysis tested associations. Results 101 patients (53% female, age 17.4 [15.0-21.1] years); disease duration 0.80 years [0.17-3.96]; post induction IUS performed 78 days [56-102] on AT (44% anti-TNF, 53% AT naïve). Segmental TM induction response across all AT was 63%. Segmental and complete TM remission was 36% and 35%, respectively (figure). Complete TM remission was seen at a higher rate with upadacitinib (UPA) than ustekinumab (UST) (p=0.009) and risankizumab (RZB) (p=0.032) but not anti-TNF (NS). Patients with severe IUS inflammation (MLS 3) at baseline were less likely to achieve TM remission independent of AT (aOR 0.21 [0.059-0.76]). Complete TM remission was independently associated with infliximab (IFX) (aOR 11.7 [2.2-62.4]) and UPA (aOR 5.22 [1.0-27.2]). Rates of segmental TM response were greater for colonic than ileal disease in UST/RZB (88% vs 47%, p=0.038), but no different in TNF/UPA. Patients started on UST/RZB after >1 failed prior AT had a trend for lower rates of TM outcomes (NS), while number of prior therapies had no impact on UPA response or remission rates. Conclusion Post-induction TM outcomes are achievable across AT: 2/3 of patients achieve segmental TM response and 1/3 achieve complete TM remission. This data, combined with the high correlation between IUS and endoscopy, suggests that IUS response could be considered as a clinical trial endpoint.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame machine prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.

metaresearch head score (Codex)0.001
metaresearch head score (Gemma)0.004
Version: metacan-v3-hybrid-931329e0061cValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Observational · Consensus signal: Observational
GenreCandidate signal: Empirical · Consensus signal: Empirical
Teacher disagreement score0.002
Threshold uncertainty score0.008

Distilled classifier scores by category (both heads)

CategoryCodexGemma
Metaresearch0.0010.004
Meta-epidemiology (narrow)0.0000.000
Meta-epidemiology (broad)0.0000.000
Bibliometrics0.0010.002
Science and technology studies0.0000.000
Scholarly communication0.0010.001
Open science0.0000.001
Research integrity0.0000.000
Insufficient payload (model declined to judge)0.0020.000

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.006
GPT teacher head0.270
Teacher spread0.264 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.

The models applied no category: nothing in the taxonomy fit this work.
Study designObservational
Domainnot available
GenreEmpirical

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations0
Published2025
Admission routes1
Has abstractyes

Explore more

Same venueJournal of Crohn s and Colitis→Same topicInflammatory Bowel Disease→French-language works237,207→